- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05970666
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
February 27, 2024 updated by: Jianbo Chen, The First Affiliated Hospital of Xiamen University
To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
71
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianbo Chen
- Phone Number: 15605921022
- Email: 274439002@qq.com
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China
- Recruiting
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Jianbo Chen
- Phone Number: 15605921022
- Email: 274439002@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age: 18 ~ 75, both male and female;
- Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular carcinoma diagnosed by pathological histology or cytology examination, and at least one measurable lesions (according to the RECIST1.1 standard, the spiral CT scan of 10mm or short diameter of 15mm);
- Patients without previous systematic treatment and inoperable resection / radical ablation surgery, but who can tolerate TACE;
- The CNLC stage is Ⅱa-Ⅲb stage;
- The Child-Pugh grade of liver function is A grade or B grade (5-7 points);
- The ECOG PS score is 0-1 points;
- Expected survival period of 12 weeks;
- If the patient has active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be <2000 IU / mL (if the study site has only copy / mL testing units, Must be <12500 copy / mL), And received at least 14 days before initiating anti-HBV treatment (according to local standard therapy, e. g. entecavir) and willing to receive antiviral treatment throughout the study; hepatitis C virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral treatment according to local standard treatment guidelines and liver function within grade CTCAE 1 elevation;
- Main organs function are normal and meet the following criteria: (1) The blood routine examination standards should be met with: (no blood transfusion within 14 days) A. Hemoglobin (HB), 90g / L, B. White blood cell count (WBC) 3109 / L C. Absolute neutrophil count (ANC) 1.5109 / L, D. Platelet (PLT) 80109 / L;(2) Biochemical examination shall meet the following standards: A. Bilirubin (BIL) <1.5 times the upper limit of normal value (ULN); B. Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST <5 ULN; C. Serum creatinine (Cr)≤1.5ULN;
- Women of childbearing age must have negative pregnancy test (serum) or urine HCG within 7 days before enrollment and are willing to use appropriate contraception during treatment and 24 weeks after the last administration of test drug; for men, surgical sterilization or agree to use appropriate contraception during and 24 weeks after the last administration of trial drug;
- The subjects volunteered to join the study and had good compliance with the follow-up.
Exclusion Criteria:
- Pregnant or lactating women;
- The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma;
- Diffuse liver cancer;
- Patients with autoimmune diseases, organ / hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ);
- Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness;
- Patients who have participated in other clinical trials in the recent three months;
- Previous history of other malignancies or have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy;
- Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment;
- Use of immunosuppressants or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose> 10mg / day prednisone or other efficacy hormones);
- Liver function was graded as Child-Pugh C, which could not be improved by liver care treatment;
- esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment;
- Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. Platelet count <50109 / L and severe coagulation abnormalities against surgery (anticoagulation therapy and / or anticoagulant therapy should be stopped for more than 1 week before radiation therapy);
- A stubborn amount of ascites, pleural fluid, malignant fluid;
- Active infection, especially the inflammation of the biliary tract system;
- Severe functional failure of the liver, kidney, heart, lung, brain and other major organs;
- Previously allergic to PD-1 / PD-L1 mAb / any component of the targeted drug or other similar trials;
- Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg);
- Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) <50%;
- Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of> 1.0g);
- Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption;
- According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study;
- Patients with radiotherapy, targeted therapy, and other contraindications to immunotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
|
TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate(ORR)
Time Frame: Up to 2 years
|
Refers to the proportion of all subjects with the best overall response (BOR) as complete remission (CR) or partial remission (PR) according to mRECIST 1.1 criteria.
|
Up to 2 years
|
Occurence of AE and SAE
Time Frame: Up to 2 years
|
Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) (NCI CTCAE 5.0)
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate(DCR)
Time Frame: Up to 2 years
|
Refers to the proportion of all subjects with the best overall response (BOR) according to mRECIST criteria as complete remission (CR), partial remission (PR) and stable disease (SD).
|
Up to 2 years
|
Radical (R0) resection rate after conversion therapy
Time Frame: Up to 2 years
|
The cut margin had no residual cancer cells
|
Up to 2 years
|
percent conversion
Time Frame: Up to 2 years
|
The ates of conversion to operable patients in inoperable patients
|
Up to 2 years
|
Pathological complete response rate (pCR)
Time Frame: Up to 2 years
|
The rate of no remaining tumor cells in the excised tissue samples
|
Up to 2 years
|
Major pathological response rate (MPR)
Time Frame: Up to 2 years
|
The ratio of the tumor cells active in the removed tissue samples is less than 10%.
|
Up to 2 years
|
Progression-free survival (PFS)
Time Frame: Up to 2 years
|
PFS was defined as the subject's date from the date of the first dose to the date of the first documented tumor progression (as assessed by mRECIST criteria, with or without continuation of treatment) or the date of death from any cause, whichever occurred first.
|
Up to 2 years
|
Relapse-free survival time (RFS)
Time Frame: Up to 2 years
|
Time from date of cure surgery to time of recurrence or death
|
Up to 2 years
|
Overall survival(OS)
Time Frame: Up to 2 years
|
Defined as the time from the date of the first dose to the death of the subject from any cause.
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Feng Lin, Ningde Mindong Hospital
- Principal Investigator: Jianbo Chen, The First Affiliated Hospital of Xiamen University
- Principal Investigator: Feng Ye, The First Affiliated Hospital of Xiamen University
- Study Director: congren Wang, Quanzhou First Hospital
- Study Director: Qinghe Cai, Affiliated Hospital of Putian University
- Study Director: Jiafei Chen, Putian First Hospital
- Study Director: Yongzhong Wang, Sanming Second Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2023
Primary Completion (Estimated)
November 15, 2026
Study Completion (Estimated)
November 15, 2026
Study Registration Dates
First Submitted
July 25, 2023
First Submitted That Met QC Criteria
July 25, 2023
First Posted (Actual)
August 1, 2023
Study Record Updates
Last Update Posted (Actual)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 27, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- 23-OBU-FJ-HCC-II-012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on TACE with adebrelimab and bevacizumab
-
Second Affiliated Hospital of Guangzhou Medical...Active, not recruitingHepatocellular Carcinoma Non-resectableChina
-
Shanghai Zhongshan HospitalRecruitingA Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCCHepatocellular Carcinoma | DonafenibChina
-
Peking University Cancer Hospital & InstituteRecruitingUnresectable Hepatocellular CarcinomaChina
-
Shanghai Pulmonary Hospital, Shanghai, ChinaJiangsu HengRui Medicine Co., Ltd.Not yet recruitingLimited Stage Small Cell Lung CancerChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
The First Affiliated Hospital of Xinxiang Medical...Not yet recruiting
-
Sun Yat-sen UniversityMinistry of Health, ChinaUnknownHepatocellular CarcinomaChina
-
Zhongzheng XiangNot yet recruitingHead and Neck Squamous Cell Carcinoma
-
Alexander KimSurefire Medical, Inc.Unknown
-
Kindai UniversityUnknownCarcinoma, Hepatocellular | Hepatocellular Carcinoma | Liver Neoplasm | Unresectable Hepatocellular CarcinomaJapan